Evidence map›Paper›PMID 38234702›Full record

ArticleThe Lancet regional health. Southeast Asia2024

Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia - a

Bharath Kumar Tirupakuzhi Vijayaraghavan, Anders Granholm, Sheila N Myatra, Vivekanand Jha, Naomi Hammond, Sharon Micallef, Marie Warrer Munch, Maj-Brit N Kjær, Morten Hylander Møller, Theis Lange and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Southeast Asia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 4 countries.

Bharath Kumar Tirupakuzhi VijayaraghavanDepartment of Critical Care Medicine, Apollo Hospitals, Chennai, India.
Anders GranholmDepartment of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Denmark.
Sheila N MyatraDepartment of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.
Vivekanand JhaThe George Institute for Global Health, New Delhi, India.
Naomi HammondCritical Care Program, The George Institute for Global Health, University of New South Wales, Australia.
Sharon MicallefCritical Care Program, The George Institute for Global Health, University of New South Wales, Australia.
Marie Warrer MunchDepartment of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Denmark.
Maj-Brit N KjærDepartment of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Denmark.
Morten Hylander MøllerDepartment of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Denmark.
Theis LangeDepartment of Public Health, Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
Anders PernerDepartment of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Denmark.
Balasubramanian VenkateshCritical Care Program, The George Institute for Global Health, University of New South Wales, Australia.
COVID-STEROID 2 collaborators
Copenhagen University Hospital · DKManipal Academy of Higher Education · INUniversity of Copenhagen · DKUNSW Sydney · AUApollo Hospitals · INHomi Bhabha National Institute · INRoyal North Shore Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the COVID-STEROID 2 trial there was suggestion of heterogeneity of treatment effects (HTE) between patients enrolled from Europe vs. India on the primary outcome. Whether there was HTE for the remaining patient-centred outcomes is unclear. Methods: In this Findings: There were differences in mortality at day 28 (RD for Europe -8.3% (99% CI: -17.7 to 1.0) vs. India 0.1% (99% CI: -10.0 to 10.0)), mortality at day 90 (RD for Europe -7.4% (99% CI: -17.1 to 2.0) vs. India -1.4% (99% CI: -12.8 to 9.8)), mortality at day 180 (RD for Europe -6.7% (99% CI: -16.4 to 2.9) vs. India -1.0% (99% CI: -12.3 to 10.3)), and number of days alive without life support at day 90 (MD for Europe 6.1 days (99% CI: -1.3 to 13.4) vs. India 1.7 days (99% CI: -8.4 to 11.8)). For serious adverse reactions, the direction was reversed (RD for Europe -1.0% (99% CI: -7.1 to 5.2) vs. India -5.3% (99% CI: -16.2 to 5.0). Interpretation: Our analysis suggests higher dose dexamethasone may have less beneficial effects for patients in India as compared with those in Europe; however, the evidence is weak, and this could represent a chance finding. Funding: None for this analysis. The COVID STEROID 2 trial was funded by The Novo Nordisk Foundation and supported by Rigshospitalet's Research Council.

Indexed as

COVID-19Developing countriesRandomised controlled trialsSteroids

Identifiers

PMID38234702
PMCPMC10794101
OpenAlexW4387301081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.